Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Melanoma 1Leukemia, Hairy Cell 1Histiocytosis 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

olutasidenib 1margetuximab 1Quality of Life 1Patient Reported Outcome Measures 1PLX8394 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Immunotherapy 1Fluorodeoxyglucose F18 1FAPI-46 1Drug Therapy 1Cytochrome P-450 CYP3A 1Cytochrome P-450 CYP2C9 1Cytochrome P-450 CYP2C8 1Cytochrome P-450 CYP2C19 1Cytochrome P-450 CYP2B6 1Cytochrome P-450 CYP1A2 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × PLX8394 × Other hematologic neoplasm × Clear all
NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Fore Biotherapeutics

Phase 1 Terminated
5 enrolled
DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡